What cannabis can learn from Covid
Hydroxychloroquine research suggests the next step for medical cannabis research
Bibliographic Data
| ID | 14908980 |
|---|---|
| Authors | Theodore L Caputi (0000-0003-3498-9032, University of York, corresponding author) |
| Year | 2021 |
| Volume | 93 |
| Pages | 103133 |
| Publication date | 2021-07-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | International Journal of Drug Policy (JOURNAL) |
| Journal identifiers | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2021.103133 |
| PMID | 33517127 |
| OpenAlex | W3126601485 |
| Language | EN |
| References cited | 26 |
2019-20 coronavirus outbreak · Betacoronavirus · Cannabis · Coronavirus disease 2019 (COVID-19 · Hydroxychloroquine · Medical cannabis · Psychiatry · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 · Cannabis and Cannabinoid Research · Epilepsy research and treatment · Medicine · Pharmaceutical studies and practices · Psychology · Virology
| Citation velocity | historical |
|---|---|
| Highly cited | No |